throbber
Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`Adam R. Brausa (Reg No.
`60,287
`Daralyn J. Durie (Pro Hac
`Vice pending)
`DURIE TANGRI LLP
`217 Leidesdorff Street
`San Francisco, CA 94111
`
`
`
`
`
`
`Filed on behalf of Patent Owner Genentech, Inc. by:
`
`
`David L. Cavanaugh (Reg. No. 36,476)
`
`Rebecca Whitfield (Reg. No. 73,756)
`Robert J. Gunther, Jr. (Pro Hac Vice pending)
`Lisa J. Pirozzolo (Pro Hac Vice pending)
`
`Kevin S. Prussia (Pro Hac Vice pending)
`
`Andrew J. Danford (Pro Hac Vice pending)
`WILMER CUTLER PICKERING
`
`
` HALE AND DORR LLP
`1875 Pennsylvania Ave., NW
`Washington, DC 20006
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`
`
`
`
`
`
`
`
`
`CELLTRION, INC.,
`Petitioner,
`
`v.
`
`GENENTECH, INC.,
`Patent Owner.
`
`
`Case IPR2017-01373
`U.S. Patent 6,407,213
`
`
`PATENT OWNER’S UNOPPOSED MOTION FOR ADMISSION PRO HAC
`VICE OF DARALYN J. DURIE UNDER 37 C.F.R. § 42.10(C)
`
`
`
`
`
`
`

`

`
`I.
`
`Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`RELIEF REQUESTED
`Pursuant to 37 C.F.R. § 42.10(c), Patent Owner Genentech, Inc.
`
`(“Genentech”) by and through its attorneys, respectfully request that the Board
`
`admit Daralyn J. Durie pro hac vice in this proceeding, IPR2017-01373.
`
`Petitioner’s counsel has indicated that it does not oppose this motion.
`
`II. GOVERNING LAW, RULES, AND PRECEDENT
`Section 42.10(c) of 37 C.F.R. provides as follows:
`
`The Board may recognize counsel pro hac vice during a proceeding
`upon a showing of good cause, subject to the condition that lead
`counsel be a registered practitioner and to any other conditions as the
`Board may impose. For example, where the lead counsel is a registered
`practitioner, a motion to appear pro hac vice by counsel who is not a
`registered practitioner may be granted upon showing that counsel is an
`experienced litigating attorney and has an established familiarity with
`the subject matter at issue in the proceeding.
`
`The Board has specified that a motion for pro hac vice admission shall be
`
`filed in accordance with the “ORDER-AUTHORIZING MOTION FOR PRO HAC
`
`VICE ADMISSION – 37 C.F.R. § 42.10” in Unified Patents, Inc. v. Parallel Iron,
`
`LLC, Case No. IPR2013-00639 (“Representative Order”). The Representative
`
`Order states that the motion must “[c]ontain a statement of facts showing there is
`
`good cause for the Board to recognize counsel pro hac vice during the
`
`proceeding,” and “[b]e accompanied by an affidavit or declaration of the individual
`
`
`
`
`
`1
`
`
`
`

`

`Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`seeking to appear” which attests to a number of facts concerning the counsel
`
`seeking admission pro hac vice specified in the Representative Order.
`
`Accompanying this motion as Exhibit 2033 is the Declaration of Daralyn J. Durie
`
`in Support of this Motion for Admission Pro Hac Vice (“Durie Decl.”).
`
`III. STATEMENT OF FACTS
`1.
`Patent Owners’ lead counsel, David L. Cavanaugh, is a registered
`
`practitioner (Reg. No. 36,476). Backup counsel, Adam Brausa (Reg. No. 60,287)
`
`and Rebecca Whitfield (Reg. No. 73,756) are also registered practitioners.
`
`2. Ms. Durie is a Partner at the law firm Durie Tangri LLP. (Durie Decl.
`
`¶ 2, Ex. 2033).
`
`3. Ms. Durie is an experienced litigating attorney and has been litigating
`
`cases relating to patents for over 20 years. (Id. ¶ 2)
`
`4. Ms. Durie is a member in good standing of the California State Bar,
`
`and among other courts, the United States Court of Appeals for the Federal Circuit
`
`(Id. ¶ 3).
`
`5. Ms. Durie has never been suspended or disbarred from practice before
`
`any court or administrative body. (Id. ¶ 5).
`
`6.
`
`No application filed under Ms. Durie for admission to practice before
`
`any court or administrative body has ever been denied. (Id. ¶ 6).
`
`7.
`
`No sanctions or contempt citations have been imposed against Ms.
`
`
`
`
`
`2
`
`
`
`

`

`Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`Durie by any court or administrative body. (Id. ¶ 7).
`
`8. Ms. Durie has read and agrees to comply with the Office Patent Trial
`
`Practice Guide and the Board's Rules of Practice for Trials set forth in part 42 of 37
`
`C.F.R. (Id. ¶ 8).
`
`9. Ms. Durie understands that she will be subject to the USPTO Rules of
`
`Professional Conduct set forth in 37 C.F.R. §§ 11.101 et seq. and disciplinary
`
`jurisdiction under 37 C.F.R. § 11.19(a). (Id. ¶ 9).
`
`10.
`
`In the last three (3) years, Ms. Durie have appeared Pro Hac Vice
`
`before the Patent Tsrial and Appeal Board in the following cases: Sanofi-Aventis
`
`U.S. LLC and Regeneron Pharmaceuticals, Inc. v. Genentech, Inc. and City of
`
`Hope, IPR2015-01624 (pro hac vice granted); Genzyme Corporation v. Genentech,
`
`Inc. and City of Hope, IPR2016-00460 (pro hac vice motion filed) (joined with
`
`IPR2015-01624); Genzyme Corporation v. Genentech, Inc. and City of Hope,
`
`IPR2016-00383 (pro hac vice motion filed) (not instituted); Merck Sharp &
`
`Dohme Corp. v. Genentech, Inc. and City of Hope, IPR2016-01373 (pro hac vice
`
`granted) (not instituted); Mylan Pharmaceuticals, Inc. v. Genentech, Inc. and City
`
`of Hope, IPR2016-00710 (pro hac vice granted) (joined with IPR2017-00047)
`
`(terminated); Mylan Pharmaceuticals, Inc. v. Genentech, IPR2016-01693 (pro hac
`
`vice motion filed) (challenging U.S. Patent No. 6,407,213, that patent at issue in
`
`this case; terminated); Mylan Pharmaceuticals, Inc. v. Genentech, IPR2016-01694
`
`
`
`
`
`3
`
`
`
`

`

`Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`(pro hac vice motion filed) (challenging U.S. Patent No. 6,407,213, that patent at
`
`issue in this case; terminated); Hospira, Inc.. v. Genentech, Inc., IPR2017-00731
`
`(pro hac vice filed June 8, 2017; institution denied July 27, 2017, request for
`
`rehearing filed August 25, 2017; instituted October 26, 2017); Hospira, Inc. v.
`
`Genentech, Inc., IPR2017-00737 (pro hac vice granted June 21, 2017); Hospira,
`
`Inc. v. Genentech, Inc., IPR2017-00739 (pro hac vice granted June 21, 2017;
`
`institution denied July 27, 2017); Hospira, Inc. v. Genentech, Inc., IPR2017-00804
`
`(pro hac vice granted October 2, 2017, pending); Hospira, Inc. v. Genentech, Inc.,
`
`IPR2017-00805 (pro hac vice granted October 2, 2017, pending); Celltrion, Inc. v.
`
`Genentech, Inc., IPR2017-01121 (pro hac vice granted October 30, 2017,
`
`pending); Celltrion, Inc. v. Genentech, Inc., IPR2017-01122 (pro hac vice granted
`
`October 30, 2017, pending); Celltrion, Inc. v. Genentech, Inc., IPR2017-01139
`
`(pro hac vice granted October 30, 2017, pending); Celltrion, Inc. v. Genentech,
`
`Inc., IPR2017-01140 (pro hac vice granted October 30, 2017, pending); Celltrion,
`
`Inc. v. Genentech, Inc., IPR2017-01374 (pro hac vice motion to be filed, pending);
`
`Pfizer, Inc. v. Genentech, Inc., IPR2017-01488 (pro hac vice granted September
`
`27, 2017, pending); Pfizer, Inc. v. Genentech, Inc., IPR2017-01489 (pro hac vice
`
`granted September 27, 2017, pending); Pfizer, Inc. v. Genentech, Inc., IPR2017-
`
`01726 (pro hac vice motion to be filed, pending); Pfizer, Inc. v. Genentech, Inc.,
`
`IPR2017-01727 (pro hac vice motion to be filed, pending); Samsung Bioepis, Co.
`
`
`
`
`
`4
`
`
`
`

`

`Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`Ltd. v. Genentech, Inc., IPR2017-01958 (pro hac vice motion to be filed, pending);
`
`Samsung Bioepis, Co. Ltd. v. Genentech, Inc., IPR2017-01959 (pro hac vice
`
`motion to be filed, pending); Samsung Bioepis, Co. Ltd. v. Genentech, Inc.,
`
`IPR2017-01960 (joined to IPR2017-00737); Pfizer, Inc. v. Genentech, Inc.,
`
`IPR2017-02019 (pro hac vice to be filed, pending); Pfizer, Inc. v. Genentech, Inc.,
`
`IPR2017-02020 (pro hac vice to be filed, pending); Boehringer Ingelheim
`
`Pharmaceuticals, Inc. v. Genentech, Inc., IPR2017-02031 (pro hac vice to be filed,
`
`pending); Boehringer Ingelheim Pharmaceuticals, Inc. v. Genentech, Inc.,
`
`IPR2017-02032 (pro hac vice to be filed, pending); Pfizer, Inc. v. Genentech, Inc.,
`
`IPR2017-02063 (pro hac vice to be filed, pending); Samsung Bioepis, Co. Ltd. v.
`
`Genentech, Inc., IPR2017-02139 (pro hac vice to be filed, pending); Samsung
`
`Bioepis, Co. Ltd. v. Genentech, Inc., IPR2017-02140 (pro hac vice to be filed,
`
`pending); Pfizer, Inc. v. Genentech, Inc., IPR2010-00016 (pro hac vice to be filed,
`
`pending); Samsung Bioepis, Co., Ltd., IPR2018-00192 (pro hac vice to be filed,
`
`pending).
`
`11. Ms. Durie has an established familiarity with the subject matter at
`
`issue in this proceeding. She has handled patent cases relating to recombinant
`
`antibodies for more than twelve years. (Id. ¶ 11). In many of these cases involving
`
`antibodies, she has represented Genentech. During these litigations, she has
`
`worked closely with Adam R. Brausa, counsel for Genentech in this matter. (Id.).
`
`
`
`
`
`5
`
`
`
`

`

`Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`12. Additionally, Ms. Durie has carefully reviewed and has developed
`
`
`
`extensive familiarity with the matters involved in and implicated by these
`
`proceedings, including the ’213 patent and its file history, the prior art presented in
`
`the petition, and the legal and factual issues raised by the Petitioner in this
`
`proceeding. As a result, Ms. Durie has acquired substantial understanding of the
`
`underlying legal and technological issues at stake in this proceeding. (Id. ¶ 12).
`
`IV. GOOD CAUSE EXISTS FOR PRO HAC VICE ADMISSION OF
`DARALYN J. DURIE
`The facts outlined above in the Statement of Facts, supported by the
`
`Declaration of Daralyn J. Durie (Ex. 2033), establish there is good cause to admit
`
`Ms. Durie pro hac vice in this proceeding under 37 C.F.R. § 42.10. Patent
`
`Owner’s lead counsel, David L. Cavanaugh, is a registered practitioner in good
`
`standing before the Board. Ms. Durie is an attorney in good standing in the State
`
`Bar of California and the United States Court of Appeals for the Federal Circuit.
`
`Ms. Durie has carefully reviewed the ’213 patent at issue in this proceeding, its
`
`prosecution history, the prior art, the grounds advanced by the Petitioner and other
`
`aspects of the record in this proceeding, and is familiar with these matters. Based
`
`on her experience and knowledge, there is good cause to admit Ms. Durie pro hac
`
`vice in this proceeding.
`
`V. CONCLUSION
`In light of the foregoing, Patent Owner respectfully requests that the Board
`
`
`
`
`
`6
`
`
`
`

`

`Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`admit Daralyn J. Durie pro hac vice in this proceeding.
`
`
`
`Dated: January 9, 2018
`
`
`
`
`
`
`
`
`
`
`
`
`By:
`
`
`Respectfully submitted,
`
`/David L. Cavanaugh/
`David L. Cavanaugh, Reg. No. 36,476
`WILMER CUTLER PICKERING
`HALE AND DORR LLP
`1875 Pennsylvania Avenue, N.W.
`Washington, D.C. 20006
`Tel.: 202-663-6000
`Fax: 202-663-6363
`
`Attorney for Patent Owner
`Genentech, Inc.
`
`
`7
`
`
`
`

`

`Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`PATENT OWNER’S EXHIBIT LIST
`IPR2017-01373
`Exhibit Name
`
`Genentech, Inc. Laboratory Notebook No. 10098 (Leonard
`Presta)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 10823 (Leonard
`Presta)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 11268 (Paul Carter)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 11643 (Paul Carter)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 10840 (John Brady)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Laboratory Notebook No. 11162 (John Brady)
`PROTECTIVE ORDER MATERIAL
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11008
`(Ann Rowland)
`PROTECTIVE ORDER MATERIAL
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11297
`(Tim Hotaling)
`PROTECTIVE ORDER MATERIAL
`Excerpts from Genentech, Inc. Laboratory Notebook No. 11568
`(Monique Carver)
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Interoffice Memorandum from Paul Carter to
`Leonard Presta and Dennis Henner
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Interoffice Memorandum from Paul Carter to
`Leonard Presta
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Synthetic DNA Requests
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Synthetic DNA Requests
`PROTECTIVE ORDER MATERIAL
`
`8
`
`
`
`
`
`Patent Owner’s
`Exhibit Number
`2001
`
`
`2002
`
`2003
`
`2004
`
`2005
`
`2006
`
`2007
`
`2008
`
`2009
`
`2010
`
`2011
`
`2012
`
`2013
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`
`Patent Owner’s
`Exhibit Number
`2014
`
`
`2015
`
`2016
`
`2017
`
`2018
`
`2019
`2020
`
`2021
`
`2022
`
`2023
`
`2024
`
`2025
`
`2026
`
`2027
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`Exhibit Name
`
`Genentech, Inc. Protein Engineering of 4D5 Status Report
`PROTECTIVE ORDER MATERIAL
`Genentech, Inc. Interoffice Memorandum re: RCC Minutes and
`Recommendations
`PROTECTIVE ORDER MATERIAL
`Declaration of Dr. Leonard G. Presta
`PROTECTIVE ORDER MATERIAL
`Declaration of Dr. Paul J. Carter
`PROTECTIVE ORDER MATERIAL
`Declaration of John Ridgway Brady
`PROTECTIVE ORDER MATERIAL
`Declaration of Irene Loeffler
`Paul Carter, et al., Humanization of the Anti-p185 Antibody for
`Human Cancer Therapy, 89 PROC. NATL. ACAD. SCI. 4285-
`4289 (1992)
`Leonard Presta, et al., Humanization of an Anti-Vascular
`Endothelial Growth Factor Monoclonal Antibody for the
`Therapy of Solid Tumors and Other Disorders, 57 CANCER
`RESEARCH 4593-4599 (1997)
`Marianne Brüggerman, et al., The Immunogenicity of Chimeric
`Antibodies, 170 J. EXP. MED. 2153-2157 (1989)
`Jatinderpal Kalsi, et al., Structure-function Analysis and the
`Molecular Origins of Anti-DNA Antibodies in Systemic Lupus
`Erythematosus, EXPERT REVIEWS IN MOLECULAR MEDICINE 1-
`28 (1999)
`Scott Gorman, et al., Reshaping a Therapeutic CD4 Antibody,
`88 PROC. NATL. ACAD. SCI. 4181-4185 (1991)
`John Isaacs, et al., Humanised Monoclonal Antibody Therapy
`for Rheumatoid Arthritis, 340 THE LANCET 748-752 (1992)
`Elvin Kabat, et al., Sequences of Proteins of Immunological
`Interest 1-23 (4th ed. 1987)
`Anna Tramontano, et al., Framework Residue 71 Is a Major
`Determinant of the Position and Conformation of the Second
`Hypervariable Region in the VH Domains of Immunoglobulins,
`215 J. MOL. BIOL. 175-182 (1990)
`
`
`
`
`
`9
`
`
`
`

`

`Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`Exhibit Name
`
`H.M. Shepard, et al., Herceptin, in THERAPEUTIC ANTIBODIES.
`HANDBOOK OF EXPERIMENTAL PHARMACOLOGY 183-219 (Y.
`Chernajovsky & A. Nissim, eds. 2008)
`Excerpt from Roche Finance Report 2016
`Modified Default Standing Protective Order and Patent
`Owner’s Certification of Agreement to Terms
`Modified Default Standing Protective Order – Redline
`Declaration of Robert J. Gunther, Jr. in Support of Motion for
`Admission Pro Hac Vice
`Declaration of Daralyn J. Durie in Support of Motion for
`Admission Pro Hac Vice
`Declaration of Lisa J. Pirozzolo in Support of Motion for
`Admission Pro Hac Vice
`Declaration of Kevin S. Prussia in Support of Motion for
`Admission Pro Hac Vice
`Declaration of Andrew J. Danford in Support of Motion for
`Admission Pro Hac Vice
`
`
`
`10
`
`
`
`
`Patent Owner’s
`Exhibit Number
`2028
`
`
`2029
`2030
`
`2031
`2032
`
`2033
`
`2034
`
`2035
`
`2036
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`

`

`Case No. IPR2017-01373
`Patent Owner’s Motion For Admission Pro Hac Vice Of Daralyn J. Durie
`
`
`
`CERTIFICATE OF SERVICE
`I hereby certify that, on January 10, 2018, I caused a true and correct copy of
`the following materials:
`
` Patent Owner’s Unopposed Motion for Pro Hac Vice Admission of Daralyn
`J. Durie
`
` Exhibit 2033
`
`
`
` Patent Owner’s Updated Exhibit List
`
`to be served via electronic mail on the following attorneys of record:
`
`
`
`
`
`Cynthia Lambert Hardman
`GOODWIN PROCTER LLP
`chardman@goodwinlaw.com
`620 Eighth Avenue, New York, NY 10018
`
`Robert V. Cerwinski
`GOODWIN PROCTER LLP
`rcerwinski@goodwinlaw.com
`620 Eighth Avenue, New York, NY 10018
`
`
`/Rebecca A. Whitfield/
`Rebecca A. Whitfield
`Reg. No. 73,756
`Wilmer Cutler Pickering Hale and Dorr LLP
`60 State Street
`Boston, MA 02109
`(617) 526-5566
`
`
`
`ActiveUS 165920452v.1
`
`
`11
`
`
`
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket